Drug taking is against the law.
吸毒是违法的。
They
drugged the guard dog.
他们给看门狗下了药。
She was arrested for taking
drugs.
她因吸毒而被捕。
She took the medication as prescribed to treat her headache.
她按照医生的指示服药来治疗头痛。
He's battling a serious addiction to prescription
drugs.
他正在与处方药物严重成瘾作斗争。
The
drug was found to be effective in reducing anxiety levels.
这种药物被发现能有效降低焦虑水平。
The police seized a large cache of illegal
drugs during a raid.
警方在突袭中缴获了大量的非法毒品。
The doctor recommended a non-addictive pain reliever for her backache.
医生建议她使用一种非成瘾性的止痛药来缓解背痛。
Many people struggle with the withdrawal symptoms when quitting
drugs cold turkey.
许多人戒毒时会经历强烈的戒断症状。
Drug testing is mandatory for athletes to ensure fair competition.
运动员必须接受药物检测以保证公平竞争。
The government has launched a campaign to combat
drug abuse in schools.
政府发起了一项运动，以打击学校里的吸毒行为。
He was arrested for possession of small amounts of recreational
drugs.
他因持有少量娱乐用毒品被捕。
The
drug trial showed promising results, but more research is needed.
药物试验显示出了积极的前景，但还需要更多的研究。
In March, Shanghai Junshi Biosciences Co Ltd announced collaboration with Singapore-based Rxilient Biotech on development and commercialization of an antibody drug through a joint venture in nine Southeast Asian nations — Thailand, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, the Philippines and Vietnam.
今年3月，上海君实生物科技有限公司宣布，通过在泰国、文莱、柬埔寨、印度尼西亚、老挝、马来西亚、缅甸、菲律宾和越南等九个东南亚国家的合资企业，与新加坡的Rxilent Biotech合作开发抗体药物并将其商业化。
Li Ning, CEO of Junshi Biosciences, said, "Southeast Asia boasts a thriving pharmaceutical innovation environment, flexible drug regulatory policies and diversified medical security systems, so it has great potential as an emerging market for innovative drugs.
君实生物首席执行官李宁表示：“东南亚拥有繁荣的医药创新环境、灵活的药品监管政策和多样化的医疗保障体系，因此它作为创新药物的新兴市场具有巨大潜力。
"The company said it is planning to launch the antibody drug in more markets.
该公司表示，计划在更多市场推出这种抗体药物。
At the end of last year, the product was approved by the United States Food and Drug Administration.
去年年底，该产品获得了美国食品药品监督管理局的批准。
As an important hub of both global pharmaceutical research and development and production, Singapore presents higher requirements for drug enterprises' R&D capability, product quality and international compliance.
作为全球药物研发和生产的重要枢纽，新加坡对制药企业的研发能力、产品质量和国际合规性提出了更高的要求。
BEIJING — A group of Chinese researchers has created a gene target therapy drug for amyotrophic lateral sclerosis, or ALS.
北京——一组中国研究人员开发了一种针对肌萎缩侧索硬化症（ALS）的基因靶向治疗药物。
SineuGene Therapeutics, a biopharmaceutical company, successfully completed a clinical drug delivery attempt of adeno-associated virus vector gene therapy for ALS.
生物制药公司SineuGene Therapeutics成功完成了腺相关病毒载体基因治疗ALS的临床药物递送尝试。
"Based on the basic research achievements in neuroscience of the Tsinghua University School of Medicine, we developed the drug and completed the transformation of the research result within two years.
“在清华大学医学院神经科学基础研究成果的基础上，我们开发了该药物，并在两年内完成了研究成果的转化。
"The company is currently promoting the drug to patients with ALS, also known as Lou Gehrig's disease.
该公司目前正在向ALS患者推广该药物，也称为Lou Gehrig病。
That also meant the drug has expanded the treatment population from late-stage to early-stage cancer patients.
这也意味着该药物已经将治疗人群从晚期癌症患者扩大到早期患者。
The supplemental new drug application for the drug in combination with chemotherapy as perioperative treatment and subsequently, monotherapy as adjuvant therapy for the treatment of adult patients with resectable stage IIIA-IIIB non-small cell lung cancer (NSCLC) has been approved by the National Medical Products Administration, the company announced Tuesday.
该公司周二宣布，国家医疗产品管理局已批准该药物与化疗联合作为围手术期治疗的补充新药申请，以及随后作为辅助治疗的单药治疗，用于治疗可切除的IIIA-IIIB期癌症（NSCLC）成年患者。
The first six indications, including as a treatment for unresectable or metastatic melanoma after the failure of standard systemic therapy, have been included in the 2023 edition of the national reimbursement drug list.
前六个适应症，包括标准全身治疗失败后不可切除或转移性黑色素瘤的治疗，已被列入2023年版的国家报销药物清单。
A novel drug production base, with an annual capacity of 250 million tablets and 550 million capsules has been put into operation, becoming the first high-end biomanufacturing project in Shanghai's Zhangjiang innovative drug industry base, Chinese biopharmaceutical company HutchMed announced on Friday.
中国生物制药公司HutchMed周五宣布，一个年产能2.5亿片、5.5亿粒胶囊的新药生产基地已投入运营，成为上海张江创新药产业基地的第一个高端生物制造项目。
Taking up an area of 43 acres, the newly completed project in Shanghai's Zhangjiang Innovation Drug Industry Base is facilitating HutchMed's pursuit of building a first-class global manufacturing center and clinical sample preparation center in China.
上海张江创新药产业基地新建成的项目占地43英亩，有助于HutchMed打造中国一流的全球制造中心和临床样品制备中心。
Being one of the city's major strategic emerging industrial projects, construction of the HutchMed's innovative drug production base started three years ago.
作为该市的重大战略性新兴产业项目之一，HutchMed的创新药物生产基地于三年前开始建设。
For example, during the China International Import Expo held in Shanghai last month, the first and only targeted drug approved in China for the treatment of chronic graft-versus-host disease (cGVHD) by French pharmaceutical company Sanofi made its Asia debut.
例如，上个月在上海举行的中国国际进口博览会期间，法国赛诺菲制药公司在中国批准的第一种也是唯一一种治疗慢性移植物抗宿主病的靶向药物首次在亚洲亮相。
Nefecon was the first-ever treatment for IgAN approved by the United States Food and Drug Administration in December 2021 and the European Medicines Agency in July 2022.
Nefecon是美国食品药品监督管理局于2021年12月和欧洲药品管理局于2022年7月批准的第一种IgAN治疗方法。
"While actively preparing for the commercial launch of Nefecon and bringing this first-in-disease therapy to patients in China as soon as possible, the company will continue to develop other innovative drug candidates in renal and auto-immune diseases to benefit more Chinese and Asian patients," he said.
他说：“在积极准备Nefecon的商业上市并尽快将这一首个疾病治疗推向中国患者的同时，该公司将继续开发其他肾脏和自身免疫疾病的创新候选药物，使更多中国和亚洲患者受益。”。
The company said that the medicine is expected to receive new drug application approval in Singapore and China's Hong Kong Special Administration soon.
该公司表示，该药有望很快在新加坡和中国香港特别行政区获得新药申请批准。
During the CIIE, Boehringer Ingelheim also exhibited a new drug candidate at the Phase-3 clinical trial for treating idiopathic pulmonary fibrosis, a rare and chronic lung disease.
在CIIE期间，勃林格殷格翰还在治疗特发性肺纤维化（一种罕见的慢性肺病）的3期临床试验中展示了一种新的候选药物。
"Through our participation in the CIIE, we've benefitted from China's further opening-up, gained valuable business opportunities in its dynamic healthcare market, and swiftly had our products approved and added into the reimbursement drug list," said Dong.
董说：“通过参加进博会，我们受益于中国的进一步开放，在其充满活力的医疗保健市场获得了宝贵的商机，并迅速将我们的产品批准并列入报销药物名单。”。
At this year's event, the company will once again present its innovative JAK inhibitor Rinvoq and pioneering hematological cancer drug Venclexta, both of which received accelerated approval thanks to their debut in the previous CIIE.
在今年的活动上，该公司将再次展示其创新的JAK抑制剂Rinvoq和开创性的血液学癌症药物Venclexta，这两种药物都因在上届进博会上首次亮相而获得了加速批准。
Dong emphasized that China's ongoing healthcare reform and the expedited new drug approval have benefited AbbVie, with Rinvoq as a particular example, which has been approved for seven indications within only 20 months after its launch in China.
董强调，中国正在进行的医疗改革和加快的新药审批使AbbVie受益，Rinvoq就是一个特别的例子，它在中国推出后仅20个月就获得了7个适应症的批准。
She expected that the pace of new drug launch in China will continue to gain momentum supported by AbbVie's ongoing or planned involvement in over 70 clinical research programs in the country.
她预计，在AbbVie正在或计划参与中国70多个临床研究项目的支持下，中国新药上市的步伐将继续加快。
In response to the country's dual carbon goals, AstraZeneca will utilize the expo to display results in promoting green and sustainable development in terms of drug research, production and operation, business models and other fields.
为响应国家的双碳目标，阿斯利康将利用博览会展示在药物研究、生产经营、商业模式等领域促进绿色可持续发展的成果。
GSK has 23 other vaccine candidates in the development stage, including a respiratory syncytial virus (RSV) vaccine, which was approved by the United States Food and Drug Administration in May for the prevention of RSV infection in people aged 60 or older.
葛兰素史克还有23种其他候选疫苗处于开发阶段，其中包括一种呼吸道合胞病毒（RSV）疫苗，该疫苗于5月被美国食品和药物管理局批准用于预防60岁或以上人群感染RSV。
The drug Sunlenca®(Lenacapavir) provides a new treatment option that only needs to be administered twice a year.
药物Sunlenca®（Lenacapavir）提供了一种新的治疗选择，每年只需给药两次。
The drug in both injection and tablet forms have been approved for market in the European Union and the US for the treatment of HIV infection in combination with other antiretrovirals in people with multi-drug resistant HIV who are heavily treatment-experienced.
该药物以注射和片剂形式已获准在欧盟和美国上市，用于与其他抗逆转录病毒药物联合治疗有丰富治疗经验的耐多药艾滋病毒患者的艾滋病毒感染。
The company said that the tablet and injection of the drug have submitted a marketing authorization application in China.
该公司表示，该药物的片剂和注射剂已提交了在中国的上市授权申请。
Shanghai Junshi Biosciences has gained approval from the United States' Food and Drug Administration for a market launch of a flagship self-developed cancer treatment, which experts said marks another milestone of domestic enterprises' innovation and production capacities.
上海君实生物科技有限公司已获得美国食品药品监督管理局的批准，推出自主研发的癌症旗舰疗法，专家表示，这标志着国内企业创新和生产能力的又一个里程碑。
In an online media conference on Monday, Yao Sheng, senior vice-president of Junshi Biosciences, said the company had signed cooperation agreements with foreign partners including Coherus, Hikma, Rxilient Biotech and Dr. Reddy's that cover more than 50 markets, and expects the drug to get greater presence worldwide following the approval from the US FDA.
在周一的一次在线媒体会议上，君实生物高级副总裁姚胜表示，该公司已与包括Cohereus、Hikma、Rxilient Biotech和Dr.Reddy’s在内的外国合作伙伴签署了涵盖50多个市场的合作协议，并预计该药物在获得美国食品药品监督管理局批准后将在全球范围内获得更大的影响力。
"The approval of the homegrown antibody is the first of its kind for treating NPC in the US, and that's a milestone for China's innovative medicine industry," said Xu Ruihua, president of Sun Yat-sen University Cancer Center, and the principal investigator of the drug.
“国产抗体的批准是美国首例用于治疗NPC的抗体，这对中国创新医药行业来说是一个里程碑，”该药物的首席研究员、中山大学癌症中心院长徐瑞华说。
"In the field of NPC treatment, China has a leading position, and the drug has demonstrated our innovations in treating cancer in the field of internal medicine," he added.
他补充道：“在全国人大治疗领域，中国处于领先地位，该药物展示了我们在内科治疗癌症方面的创新。”。
According to a press release from the companies, Jong Chul Park, assistant professor at Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center, said that the drug, a new treatment option demonstrating the ability to significantly improve progress-free survival and overall survival of patients, should quickly emerge as the new standard of care when used in combination with chemotherapy.
根据两家公司的新闻稿，哈佛医学院助理教授、马萨诸塞州总医院癌症中心头颈癌中心的主治医师朴钟哲（Jong Chul Park）表示，该药物是一种新的治疗选择，表明有能力显着提高患者的无进展生存率和总体生存率，当与化疗联合使用时，应迅速成为新的护理标准。
China has been stepping up efforts to improve its business environment for drug innovation.
中国一直在加大力度改善药品创新的营商环境。
In addition, among the approved products, seven are included in the National Reimbursement Drug List.
此外，在批准的产品中，有7种被列入《国家报销药品目录》。
The product, which received approval from the United States Food and Drug Administration in July, will be making its Asia debut at the expo.
该产品于7月获得美国食品和药物管理局的批准，将在博览会上首次在亚洲亮相。
"The number of drugs included in the National Reimbursement Drug List has significantly increased.
“列入国家报销药品目录的药品数量显著增加。
In addition, guidelines were launched to accelerate the landing of foreign-invested pharmaceutical projects and to optimize the drug review and approval process for MNCs in the country.
此外，还推出了加快外商投资制药项目落地的指导方针，优化跨国公司在华药品审评和审批流程。
We are witnesses of the local government's efforts in supporting R&D and innovative drug reviews and approvals.
我们见证了当地政府在支持研发和创新药物审查和批准方面所做的努力。
Shanghai-based biopharmaceutical company Zai Lab announced on Tuesday that the sales of its drug Vyvgart has officially started in China.
总部位于上海的生物制药公司Zai Lab周二宣布，其药物Vyvgart已正式开始在中国销售。
The drug was approved in China in late June.
该药物于6月下旬在中国获得批准。
Basil mentioned that the company recently has two blockbuster products - a medicine to treat obesity in some international markets and diabetes in some others as well as another potential drug achieving good results in Alzheimer's disease researches.
巴西尔提到，该公司最近推出了两款重磅产品——一种在一些国际市场治疗肥胖的药物，另一种在阿尔茨海默病研究中取得良好效果的潜在药物。
Basil said he expected the potential drug will become a game changer for patients.
巴西尔说，他预计这种潜在的药物将改变患者的游戏规则。
Zhu Duming, leader and chief physician of the critical care department at Shanghai Zhongshan Hospital, said that the launch of the medicine in China will help doctors tackle challenges related to clinical drug resistance.
上海中山医院重症监护科主任医师、主任医师朱杜明表示，该药物在中国的推出将有助于医生应对与临床耐药性相关的挑战。
"The company will continue to advance the approval and commercialization of other drug candidates to further address urgent unmet needs in China and the rest of Asia," he said.
他说：“该公司将继续推进其他候选药物的审批和商业化，以进一步解决中国和亚洲其他地区尚未满足的紧迫需求。”。
Besides, several of its innovative products in the areas of autoimmune, cardiovascular and kidney diseases as well as diabetes have been included in the latest version of the National Reimbursement Drug List.
此外，其在自身免疫、心血管和肾脏疾病以及糖尿病领域的一些创新产品已被列入最新版本的国家报销药物清单。
For example, government policies related to optimizing the business environment, speeding up the review of new drug approvals, and access to medical insurance helped bring our innovative health solutions to more people in China quickly," Charmeil said.
例如，与优化营商环境、加快新药审批和医疗保险相关的政府政策有助于将我们的创新健康解决方案迅速带给中国更多的人，”Charmeil说。
ViiV Healthcare's Dovato, the world's first dual drug regimen, was marketed in China in 2021.
ViiV Healthcare的Dovato是世界上第一个双药方案，于2021年在中国上市。
It was the first single tablet, dual drug treatment for HIV infection that needs to be taken just once a day, Carey said during her visit to China last week.
凯里上周访问中国时说，这是第一种每天只需服用一次的单片、双药治疗艾滋病毒感染的药物。
"I am really pleased to see how quickly we received the approval for our innovative drugs, and the inclusion of some of them in the country's National Reimbursement Drug List," he said.
他说：“我真的很高兴看到我们的创新药物如此迅速地获得批准，并将其中一些药物列入国家报销药物清单。”。
On July 10, Bayer and Peking University said they would extend their collaboration to foster the translation of basic research into drug discovery and development, while accelerating scientific research on cutting-edge technologies across the pharmaceutical value chain.
7月10日，拜耳和北京大学表示，他们将扩大合作，促进基础研究转化为药物发现和开发，同时加快整个制药价值链尖端技术的科学研究。
So far, Bayer and the two prestigious universities have carried out a total of 99 joint research projects on drug discovery and innovation.
到目前为止，拜耳和这两所著名大学共开展了99个药物发现和创新的联合研究项目。
With the improved drug innovation environment, 109 new drugs were approved by the National Medical Products Administration between 2018 and 2022, including 12 first-in-class drugs, according to data from the China Chamber of Commerce for Import and Export of Medicines and Health Products.
根据中国药品和保健品进出口商会的数据，随着药品创新环境的改善，2018年至2022年间，国家医疗产品管理局批准了109种新药，其中包括12种一类药物。
Since 2022, Switzerland-based Novartis has seen 100 percent of its drug development in China achieve simultaneous development with markets worldwide, significantly narrowing the time gap between launches of new drugs in China and globally, said a senior executive of the pharmaceutical company.
总部位于瑞士的诺华制药公司的一位高管表示，自2022年以来，该公司在中国的药物开发100%实现了与全球市场的同步开发，大大缩小了新药在中国和全球上市之间的时间差距。
It was a major breakthrough and the company was quite agile in this respect in the industry, said Shreeram Aradhye, president of global drug development and chief medical officer for Novartis.
诺华公司全球药物开发总裁兼首席医疗官Shreram Aradhye表示，这是一个重大突破，该公司在这方面在行业中相当灵活。
"It often used to be three or five years behind for a new drug to enter China after its launch in the global market — depending on the Chinese patient data that we were waiting for.
“过去，一种新药在全球市场上市后进入中国通常要晚三到五年——这取决于我们正在等待的中国患者数据。
He added that the company is fairly rigorous in being very aware of what therapies are available and what its peer companies are working on, and then identifies rigorously the profile of a new drug that is required for it to be competitive and bring real value to patients and the healthcare system.
他补充说，该公司非常严格地了解可用的疗法和同行公司正在研究什么，然后严格确定新药的概况，使其具有竞争力并为患者和医疗系统带来真正的价值。
Some of the therapeutic areas are also in line to help the country reduce burdens from an aging population and chronic diseases, said Rose Gao, who leads the company's drug development in China.
该公司在中国的药物开发负责人Rose Gao说，一些治疗领域也有望帮助国家减轻人口老龄化和慢性病带来的负担。
According to US industrial media Fierce Biotech, last year, the top 10 global pharmaceutical companies in terms of major business revenue cut a total of more than 50 drug development pipelines while global biopharmaceutical investment began to slow in 2022 after experiencing two years of fairly high levels during the COVID-19 pandemic.
据美国工业媒体Fierce Biotech报道，去年，全球主要业务收入排名前十的制药公司削减了总共50多条药物开发管道，而全球生物制药投资在新冠肺炎大流行期间经历了两年的高水平后，于2022年开始放缓。
Market consultancy Gartner predicts that by 2025, generative AI will account for 10 percent of all data created, compared with less than 1 percent in 2022, and could be used for a range of activities like creating software code, facilitating drug development and targeted marketing.
市场咨询公司Gartner预测，到2025年，生成性人工智能将占所有创建数据的10%，而2022年不到1%，并可用于创建软件代码、促进药物开发和定向营销等一系列活动。
Beaufort-Ipsen (Tianjin) Pharmaceutical Co Ltd inked a deal with Shenzhen Wanhe Pharmaceutical Co Ltd on Monday, in an effort to increase its drug accessibility in China.
周一，Beaufort-Ipsen（天津）制药有限公司与深圳万和制药有限公司签署了一项协议，以提高其在中国的药品可及性。
The agreement was signed to promote the early entry of Beaufort-Ipsen's new intestinal preparation drug to benefit more patients in China.
签署该协议是为了促进Beaufort Ipsen的新型肠道制剂药物尽早进入中国，使更多患者受益。
"The intestinal preparation drug from Beaufort-Ipsen is a French product and will be listed in the Chinese market this year.
“Beaufort Ipsen的肠道制剂药物是法国产品，今年将在中国市场上市。
As the first Chinese drug brand widely recognized in Africa, Artesun (Artesunate for Injection), independently developed and manufactured by Fosun Pharma, has treated over 56 million patients with severe malaria worldwide.
作为第一个在非洲获得广泛认可的中国药品品牌，复星医药自主研发生产的Artesun（注射用青蒿琥酯）已在全球治疗了5600多万名重症疟疾患者。
Amid an ongoing cancer drug shortage, the United States Food and Drug Administration has been working with Chinese drugmaker Qilu Pharmaceutical Co Ltd to import the oncological medication cisplatin.
在癌症药物持续短缺的情况下，美国食品药品监督管理局一直在与中国制药商齐鲁制药有限公司合作进口肿瘤药物顺铂。
Qilu said in a statement on its official WeChat account that it received an urgent email from the FDA in March, calling for cisplatin supply amid US drug shortages.
齐鲁制药在其官方微信账号上的一份声明中表示，它在3月份收到了美国食品药品监督管理局的一封紧急电子邮件，呼吁在美国药品短缺的情况下供应顺铂。
As reported by CNN, cancer treatments are among the hardest-hit as the US faces a near-record number of drug shortages.
据美国有线电视新闻网报道，癌症治疗是最困难的，因为美国面临着数量接近记录的药物短缺。
As of the end of March, about two dozen chemotherapy drugs were in active shortage, the fifth most of any drug category, said the University of Utah Drug Information Service.
犹他大学药物信息服务中心表示，截至3月底，约有20多种化疗药物严重短缺，在所有药物类别中排名第五。
"Despite some US politicians advocating decoupling, the temporary US imports of the unapproved Chinese drug again underline the strong economic and trade ties between the two countries, which is underpinned by China's resilient industrial and supply chains, according to Chen Jia, an independent researcher on international strategy.
“尽管一些美国政客主张脱钩，但美国暂时进口这种未经批准的中国药物再次突显了两国之间牢固的经贸关系，而中国有韧性的产业链和供应链正是这种关系的基础，”国际战略独立研究员陈佳表示。
The public welfare program, launched by Beaufour-Ipsen, Jzj Health Drug Store, Shuyu Drugstore Co Ltd and Huashi Pharmacy, called for joint efforts from all walks of life to enhance consumers' attention to intestinal health and safeguard the health of more consumers.
此次公益活动由博思益普生、Jzj健康药店、蜀渝药店有限公司和华氏大药房共同发起，呼吁社会各界共同努力，增强消费者对肠道健康的关注，保障更多消费者的健康。
The company will also reform its medical practices, and share revolutionary new drug research and development and manufacturing technologies, innovative therapies and new drugs with China, to contribute more to the development of China's pharmaceutical industry through cross-border integration, Wayne Shi, president of Sanofi Greater China, told China Daily in an exclusive interview.
赛诺菲大中华区总裁石在接受《中国日报》专访时表示，赛诺菲还将改革医疗实践，与中国分享革命性的新药研发和制造技术、创新疗法和新药，通过跨境融合为中国医药行业的发展做出更大贡献。
Following its official market release of an innovative drug into the Chinese mainland market for the treatment of adults with insufficiently controlled type 2 diabetes mellitus, the company plans to invest hundreds of millions of yuan in the Beijing manufacturing site, Shi said.
施说，在一种用于治疗2型糖尿病患者的创新药物正式进入中国大陆市场后，该公司计划在北京的生产基地投资数亿元。
The company has also established strategic partnerships with various China-based biotech and tech companies such as Innovent Biologic, Insilico Medicine, Adagene and Baidu, to accelerate its pace in fields including oncology, AI drug discovery and antibody development technology.
该公司还与Innovent Biologic、Insilico Medicine、Adagene和百度等多家中国生物技术公司建立了战略合作伙伴关系，以加快其在肿瘤学、人工智能药物发现和抗体开发技术等领域的步伐。
The software analyzes important data such as outpatient registration volume, physician workload and drug consumption, and the results can assist medical institutions in formulating work plans and making drug storage decisions.
该软件分析门诊挂号量、医生工作量和药物消耗等重要数据，其结果可以帮助医疗机构制定工作计划和做出药物储存决策。
The events, launched by Beijing Bethune Charitable Foundation, are aimed at slowing down the recurrence of psoriasis and promoting drug innovation that leads the standardized treatment of the disease.
这些活动由北京白求恩慈善基金会发起，旨在减缓银屑病的复发，促进药物创新，引领银屑病的标准化治疗。
"In the future, Janssen will continue to leverage its advantages and experience in global drug research and development, to strengthen the investment in innovative drug R&D.
“未来，杨森将继续利用其在全球药物研发方面的优势和经验，加强对创新药物研发的投资。
So far, the zone has established relations with some 80 medical device and drug manufacturers in 18 countries, according to the local government.
据当地政府称，到目前为止，该地区已与18个国家的约80家医疗器械和药品制造商建立了关系。
With the Chinese government's commitments to and policy support in accelerating new drug approvals to address the urgent clinical needs of the people, Gilead is doubling down the efforts to strengthen its development capability in China, so that more global phase-3 clinical trials will be conducted in China at a same pace with other key markets and accelerate the introduction of innovative treatments to the China market, the executive said.
随着中国政府在加快新药审批以满足人民迫切临床需求方面的承诺和政策支持，吉利德正在加倍努力加强其在中国的开发能力，这位高管表示，因此，更多的全球3期临床试验将以与其他关键市场相同的速度在中国进行，并加快将创新疗法引入中国市场。
He also said the company has been forging stronger partnerships with local stakeholders, to strengthen online and offline sales channels as well as increasing its presence in in-hospital and outside-hospital drug markets.
他还表示，该公司一直在与当地利益相关者建立更强有力的合作伙伴关系，以加强在线和线下销售渠道，并增加其在院内和院外药品市场的影响力。
Nirsevimab, the world's first broadly protective option against respiratory syncytial virus (RSV) designed for infants, has been granted the breakthrough therapy designation by the Center for Drug Evaluation of the National Medical Products Administration.
Nirsevimab是世界上第一种针对婴儿设计的呼吸道合胞病毒（RSV）的广泛保护性选择，已被国家医疗产品管理局药物评估中心授予突破性治疗指定。
Among the 10 products, seven are included in the National Reimbursement Drug List.
在这10种产品中，有7种被列入《国家报销药品目录》。
Between 2008 and 2020, funds raised related to drug innovation exceeded 20 billion yuan ($2.9 billion).
2008年至2020年间，与药物创新相关的募集资金超过200亿元人民币（29亿美元）。
In 2015, the completion of the reform for the drug and medical device approval system attracted huge capital inflow into biopharmaceutical R&D.
2015年，药品和医疗器械审批制度改革的完成吸引了大量资金流入生物制药研发。
In addition, efforts should be made to improve the transparency of drug review and approval, as well as strengthen intellectual property rights protection.
此外，应努力提高药品审评和审批的透明度，并加强知识产权保护。
In December 2022, the company's innovative rare skin disease medication, Spevigo, was approved by China's National Medical Products Administration, making it the first innovative drug developed by a multinational pharmaceutical company to be registered and approved almost simultaneously in China and around the world.
2022年12月，该公司的罕见皮肤病创新药物Spevigo获得中国国家医疗产品管理局的批准，成为第一个由跨国制药公司开发的几乎同时在中国和世界各地注册和批准的创新药物。
She raised the example of Savolitinib, a drug co-developed with leading Chinese company Hutchmed.
她举了Savolitinib的例子，这是一种与中国领先的Hutchmed公司共同开发的药物。
The drug achieved approval in China in 2021 and AstraZeneca is developing its global approvals for both lung and gastric cancer drugs.
该药物于2021年在中国获得批准，阿斯利康正在开发其肺癌和胃癌药物的全球批准。
She also mentioned that artificial intelligence has been used throughout new drug discoveries and the development process.
她还提到，人工智能已经被用于新药的发现和开发过程。
And in January this year, it settled the intelligent drug synthesis project in Suzhou of East China's Jiangsu province.
今年1月，该公司将智能药物合成项目落户中国东部江苏省苏州市。
"The multi-million euros expansion project of Bayer's Beijing Pharmaceuticals plant will be completed this year and it is expected to boost our prescription drug production capacities by 40 percent and largely enhance our capability to meet Chinese patients' medical needs," he said.
他说：“拜耳北京制药厂数百万欧元的扩建项目将于今年完成，预计这将使我们的处方药生产能力提高40%，并大大提高我们满足中国患者医疗需求的能力。”。
Bayer China Academic Collaboration Award aims to honor distinguished scholars from prestigious Chinese universities and recognize their outstanding achievements in life sciences, medical science as well as drug research and development, to strengthen communication and coordination between the pharmaceutical industry and academia and to advance basic research applied to the research and development of new drugs, thus accelerating breakthrough innovations that will benefit patients.
拜耳中国学术合作奖旨在表彰中国著名大学的杰出学者，表彰他们在生命科学、医学和药物研发方面的杰出成就，加强制药行业与学术界的沟通与协调，推进基础研究应用于新药研发，从而加快有利于患者的突破性创新。
To further strengthen translation of early innovation in drug discovery and support scientific exploration driven by Chinese investigators, Bayer and Tsinghua launched the Bayer Microfunding last year.
为了进一步加强药物发现早期创新的转化，支持中国研究人员推动的科学探索，拜耳和清华去年启动了拜耳微基金。
"The strategic partnership between Peking University and Bayer has perfectly integrated Peking University's scientific expertise with Bayer's know-hows on drug research and development.
“北京大学与拜耳的战略合作伙伴关系将北京大学的科学专业知识与拜耳在药物研发方面的专业知识完美融合。
The collaboration during the past eight years have yielded fruitful outcomes, including new scientific discoveries, and licensing opportunities of drug assets to the company founded by a professor from Peking University.
在过去的八年里，合作取得了丰硕的成果，包括新的科学发现，以及将药物资产授权给北京大学教授创立的公司的机会。
As the second session of Innovation Inspired by Partnering at the themed event, Dr Li Chen, founder and CEO of Hua Medicine, shared insights from his three-decade long career in drug R&D and introduced successful experience learned from the clinical development of dorzagliatin.
华医药创始人兼首席执行官李晨博士作为主题活动的第二期“合作启发创新”，分享了他三十年药物研发生涯的真知灼见，并介绍了多扎利痛临床开发的成功经验。
In addition to the Academic Collaboration Awards, the company established long-term strategic partnerships with local institutions Shanghai institute of Organic Chemistry, Tsinghua University and Peking University, aiming to complement Bayer's industrial know-hows with expertise of China's research institutions in exploring cutting-edge innovation, thus accelerating translation of early research into new drug discovery for addressing unmet medical needs.
除了学术合作奖，该公司还与当地机构上海有机化学研究所、清华大学和北京大学建立了长期战略合作伙伴关系，旨在用中国研究机构在探索前沿创新方面的专业知识来补充拜耳的工业知识，从而加速将早期研究转化为新药发现，以满足未满足的医疗需求。
As of the end of 2022, Bayer and these three academic partners have carried out more than 110 research collaboration projects, including discovery and structural analysis of novel targets, pathogenesis and drug mechanism of action research, drug screening, efficacy evaluation as well as exploration on new modalities, new synthetic methods and innovative formulations, covering multiple therapeutic areas, such as, oncology, cardiovascular diseases, hematology and women's health.
截至2022年底，拜耳与这三个学术合作伙伴已开展了110多个研究合作项目，包括新靶点的发现和结构分析、发病机制和药物作用机制研究、药物筛选、疗效评估以及新模式、新合成方法和创新制剂的探索，涵盖肿瘤学、心血管疾病、血液学和妇女健康等多个治疗领域。
The US Food and Drug Administration announced earlier this week that it had approved a medicine from Luye Pharma Group for the treatment of schizophrenia in adults and as monotherapy or adjunctive therapy for the maintenance treatment of bipolar I disorder in adults.
美国食品和药物管理局本周早些时候宣布，已批准鹿野制药集团的一种药物用于治疗成人精神分裂症，并作为成人双相情感障碍维持治疗的单一疗法或辅助疗法。
"Working with internet-based companies, multinational corporations get closer to patients, accelerating their drug research and development process, so that they can offer personalized, instant medical products and services to patients," said Hong Yong, associate research fellow of the e-commerce research department under the Ministry of Commerce.
商务部电子商务研究司副研究员洪勇表示：“跨国公司与互联网公司合作，拉近了与患者的距离，加快了药物研发进程，从而可以为患者提供个性化的即时医疗产品和服务。”。